<DOC>
	<DOC>NCT03096457</DOC>
	<brief_summary>This protocol will compare topical paromomycin to standard intralesional (IL) antimony (Sb) to placebo for L braziliensis in Bolivia.</brief_summary>
	<brief_title>Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia</brief_title>
	<detailed_description>Patients will be randomized between Paromomycin cream applied topically once daily for 20 days (group 1--40 patients), pentamidine administered intralesionally at 120 ug/mm2 on days 1, 3, 5 (group 2—20 patients), and cream vehicle applied topically once daily for 20 days (group 3—20 patients). After treatment, all patients will be followed for 1, 3, and 6 months.</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis, Cutaneous</mesh_term>
	<mesh_term>Leishmaniasis, Mucocutaneous</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<mesh_term>Paromomycin</mesh_term>
	<criteria>Gender: Male or female Age: &gt;12 yrs of age Presentation: 1to2 ulcerative lesions, each &lt; 30 mm in largest diameter and with a total lesion area &lt;900 mm2. Parasitology: Parasitological confirmation of the lesion will be made by visualization or culture of Leishmania from the biopsy or aspirate of the lesion. Previous treatment for leishmaniasis with Sb, pentamidine, amphotericin B, miltefosine, imidazoles, allopurinol in the last 3 months. Other diseases that would be likely in the PI's opinion to interact, either positively or negatively, with treatment.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>leishmaniasis</keyword>
	<keyword>L.braziliensis</keyword>
	<keyword>paromomycin cream</keyword>
	<keyword>intralesional pentamidine</keyword>
	<keyword>leishmaniasis local therapy</keyword>
</DOC>